|Table of Contents|

Clinical correlation analysis of LC3B+EVs,MDSC and cytokines in peripheral blood of colorectal cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 09
Page:
1652-1657
Research Field:
Publishing date:

Info

Title:
Clinical correlation analysis of LC3B+EVs,MDSC and cytokines in peripheral blood of colorectal cancer patients
Author(s):
TAO Xiaye; SHAO Xiaoyi
Medical School,Nantong University,Jiangsu Nantong 226001,China.
Keywords:
colorectal cancer; LC3B; myeloid-derived suppressor cell; cytokine
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2024.09.014
Abstract:
Objective:To investigate the levels and clinical correlations of LC3B+EVs,myeloid-derived suppressor cell (MDSC),and various cytokines in peripheral blood of colorectal cancer (CRC) patients in Danyang area.Methods:Flow cytometry was used to detect LC3B+EVs and the levels of MDSC,PMN-MDSC and M-MDSC in peripheral blood of two groups of healthy individuals and CRC patients,and to discuss the clinical correlation between LC3B+EVs and MDSC.And multi factor detection was performed on the effector molecules in the plasma samples of CRC patients,and the correlation between LC3B+EVs and various factors was discussed.Results:Compared with the control group,the number of LC3B+EVs in the peripheral blood of CRC patients significantly increased (P＜0.000 1),and there was no statistically significant difference with the patient's age and gender (P=0.869 0,P=0.971 2).There was a statistically significant increase in MDSC,PMN-MDSC,and M-MDSC in the peripheral blood of CRC patients,with PMN-MDSC mainly increasing (P＜0.000 1).There was no correlation between the levels of LC3B+EVs and MDSC and PMN-MDSC in peripheral blood of CRC patients (r=-0.002 699,P=0.989 1,r=-0.0443 5,P=0.822 7),but were significantly positively correlated with M-MDSC (r=0.481 1,P=0.009 6).LC3B+EVs in peripheral blood of CRC patients with IL-1β,IL-2,IL-4,IL-8,IL-17 and IFN-γ were positively correlated (r=0.703 1,r=0.782 7,r=0.466 3,r=0.590 1,r=0.458 9,r=0.465 5,P＜0.05),especially with IL-1β，there was a significant positive correlation (P=0.001 6).And there was not a significant positive correlation with the level of IL-5,IL-6,IL-10,IL-12,TNF- α (P＞0.05).Conclusion:The number of LC3B+EVs and MDSC levels in the plasma of CRC patients are significantly higher than those of healthy individuals.There is a significantly positive correlation between LC3B+EVs and the accumulation of M-MDSC subgroups and IL-1β,which may induce increased release of autophagosomes from CRC tumor cells,and there may be interactions between them that affect the occurrence and development of CRC.

References:

［1]QUANTE M,VARGA J,WANG TC,et al.The gastrointestinal tumor microenvironment ［J］.Gastroenterology,2013,145(1):63-78.
［2]ZHOU M,WEN Z,CHENG F,et al.Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-kappaB signal pathway ［J］.Oncoimmunology,2016,5(7):1-15.
［3]WEN ZF,LIU H,GAO R,et al.Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1［J］.J Immunother Cancer,2018,6(1):151.
［4]CHEN Y,LI P,PAN N,et al.Tumor-released autophagosomes induces CD4+ T cell-mediated immunosuppression via a TLR2-IL-6 cascade ［J］.Journal for Immunotherapy of Cancer,2019,7(1):178.
［5]SUN X,WANG X,YAN C,et al.Tumor cell-released LC3-positive EVs promote lung metastasis of breast cancer through enhancing premetastatic niche formation［J］.Cancer Sci,2022,113(10):3405-3416.
［6]DIAZ-MONTERO CM,SALEM ML,NISHIMURA MI,et al.Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage,metastatic tumor burden,and doxorubicin-cyclophosphamide chemotherapy ［J］.Cancer Immunol Immunother,2009,58(1):49-59.
［7]POREMBKA MR,MITCHEM JB,BELT BA,et al.Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth ［J］.Cancer Immunol Immunother,2012,61(9):1373-1385.
［8]WANG L,CHANG EW,WONG SC,et al.Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins ［J］.J Immunol,2013,190(2):794-804.
［9]CASSETTA L,BAEKKEVOLD ES,BRANDAU S,et al.Deciphering myeloid-derived suppressor cells:isolation and markers in humans,mice and non-human primates ［J］.Cancer Immunol Immunother,2019,68(4):687-697.
［10]BRONTE V,BRANDAU S,CHEN SH,et al.Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards ［J］.Nat Commun,2016,7(1):12150.
［11]OHKI SSM,GONDA K.Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression,inflammation and hypoproteinemia in patients with cancer ［J］.Oncology Reports,2012,28(2):453-458.
［12]NAGARAJ S,SCHRUM AG,CHO HI,et al.Mechanism of T cell tolerance induced by myeloid-derived suppressor cells ［J］.J Immunol,2010,184(6):3106-3116.
［13]SAFARZADEH E,ORANGI M,MOHAMMADI H,et al.Myeloid-derived suppressor cells:Important contributors to tumor progression and metastasis ［J］.J Cell Physiol,2018,233(4):3024-3036.
［14]TIAN X,MA J,WANG T,et al.Long non-coding RNA hoxa transcript antisense RNA myeloid-specific 1-HOXA1 axis downregulates the immunosuppressive activity of myeloid-derived suppressor cells in lung cancer ［J］.Front Immunol,2018,9:473.
［15]BRUGER AM,DORHOI A,ESENDAGLI G,et al.How to measure the immunosuppressive activity of MDSC:assays,problems and potential solutions［J］.Cancer Immunol Immunother,2019,68(4):631-644.
［16]ZHOU W,KE SQ,HUANG Z,et al.Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth［J］.Nat Cell Biol,2015,17(2):170-182.
［17]SAMBI M,BAGHERI L,SZEWCZUK MR.Current challenges in cancer immunotherapy:multimodal approaches to improve efficacy and patient response rates ［J］.J Oncol,2019,2019:1-12.
［18]LIPSON EJ,FORDE PM,HAMMERS HJ,et al.Antagonists of PD-1 and PD-L1 in cancer treatment ［J］.Semin Oncol,2015,42(4):587-600.
［19]ZHANG Y,XU J,ZHANG N,et al.Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies ［J］.Cancer Lett,2019,458:123-135.
［20]SIEMISKA I,WGLARCZYK K,WALCZAK M,et al.Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery ［J］.Transl Oncol,2022,17:101346.
［21］乐红红,相芬芬,康向东.髓源抑制性细胞在结直肠癌中的研究进展 ［J］. 现代肿瘤医学，2017,25(21):3547－3550. YUE HH,XIANG FF,KANG XD.The research progress of myeloid-derived suppressor cells in colorectal cancer［J］.Modern Oncology，2017,25(21):3547－3550.
［22]WANG Y,LIU H,ZHANG Z,et al.G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition ［J］.J Immunother Cancer,2023,11(6):e006166.
［23]李长新,周滔,郑娇,等.Beclin1、LC3B在不同分化胃腺癌组织中的表达及与Hp感染的关系 ［J］.现代肿瘤医学,2020,28(1):83-88. LI CX,ZHOU T,ZHENG J,et al.Expressions of Beclin1 and LC3B in tissues of gastric adenocarcinoma with different differentiation degrees and associations of Beclin1,LC3B with Hp infection［J］.Modern Oncology,2020,28(1):83-88.
［24]ZHAO H,YANG M,ZHAO J,et al.High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer ［J］.Med Oncol,2013,30(1):475.
［25]HU D,HUO Y,XUE Y,et al.Clinical application of autophagy proteins as prognostic biomarkers in colorectal cancer:a meta-analysis ［J］.Future Oncol,2022,18(31):3537-3549.
［26]SHEN N,WANG L,WU J,et al.Meta-analysis of the autophagy-associated protein LC3 as a prognostic marker in colorectal cancer ［J］.Exp Ther Med,2023,26(4):492.
［27]TU S,BHAGAT G,CUI G,et al.Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice ［J］.Cancer Cell,2008,14(5):408-419.
［28]SPIEGEL A,BROOKS MW,HOUSHYAR S,et al.Neutrophils suppress intraluminal nk cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells ［J］.Cancer Discov,2016,6(6):630-649.
［29]TULOTTA C,LEFLEY DV,MOORE CK,et al.IL-1B drives opposing responses in primary tumours and bone metastases,harnessing combination therapies to improve outcome in breast cancer ［J］.NPJ Breast Cancer,2021,7(1):95.

Memo

Memo:
National Natural Science Foundation of China（No.81801580）;国家自然科学基金面上项目（编号：81801580）;国家自然科学基金青年科学基金（编号：81771767）
Last Update: 2024-03-29